

TOXICOLOGICAL PROFILE FOR DICHLOROBENZENES

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

August 2006

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

A Toxicological Profile for dichlorobenzenes, Draft for Public Comment was released in September 2004. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
1600 Clifton Road NE
Mailstop F-32
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Julie Louise Gerberding, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

- Section 1.6** **How Can (Chemical X) Affect Children?**
- Section 1.7** **How Can Families Reduce the Risk of Exposure to (Chemical X)?**
- Section 3.7** **Children's Susceptibility**
- Section 6.6** **Exposures of Children**

Other Sections of Interest:

- Section 3.8** **Biomarkers of Exposure and Effect**
 - Section 3.11** **Methods for Reducing Toxic Effects**
-

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110 **Fax:** (770) 488-4178
E-mail: atsdric@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental*

Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Malcolm Williams, DVM, Ph.D.
ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

Stephen Bosch, B.S.
Daniel Plewak, B.S.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for 1,2-, 1,3-, and 1,4-dichlorobenzenes. The panel consisted of the following members:

1. Dr. Olen Brown, Emeritus Research Professor, University of Missouri, 527 North Cedar Lake Drive West, Columbia, Missouri;
2. Dr. Robert Michaels, President, RAM TRAC Corporation, 3100 Rosendale Road, Schenectady, New York; and
3. Dr. Clint Skinner, President, Skinner Associates, 3985 Shooting Star Road, Creston, California.

These experts collectively have knowledge of dichlorobenzenes' physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	iv
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	x
CONTENTS	xii
LIST OF FIGURES	xvi
LIST OF TABLES	xviii
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT ARE DICHLOROBENZENES?	1
1.2 WHAT HAPPENS TO DICHLOROBENZENES WHEN THEY ENTER THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO DICHLOROBENZENES?	3
1.4 HOW CAN DICHLOROBENZENES ENTER AND LEAVE MY BODY?	4
1.5 HOW CAN DICHLOROBENZENES AFFECT MY HEALTH?	5
1.6 HOW CAN DICHLOROBENZENES AFFECT CHILDREN?	6
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO DICHLOROBENZENES?	7
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO DICHLOROBENZENES?	8
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	8
1.10 WHERE CAN I GET MORE INFORMATION?	9
2. RELEVANCE TO PUBLIC HEALTH	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO DICHLOROBENZENES IN THE UNITED STATES	11
2.2 SUMMARY OF HEALTH EFFECTS	12
2.3 MINIMAL RISK LEVELS (MRLs)	21
3. HEALTH EFFECTS	53
3.1 INTRODUCTION	53
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	53
3.2.1 Inhalation Exposure	54
3.2.1.1 Death	77
3.2.1.2 Systemic Effects	78
3.2.1.3 Immunological and Lymphoreticular Effects	95
3.2.1.4 Neurological Effects	96
3.2.1.5 Reproductive Effects	97
3.2.1.6 Developmental Effects	99
3.2.1.7 Cancer	100
3.2.2 Oral Exposure	101
3.2.2.1 Death	102
3.2.2.2 Systemic Effects	152

3.2.2.3	Immunological and Lymphoreticular Effects.....	182
3.2.2.4	Neurological Effects.....	183
3.2.2.5	Reproductive Effects.....	185
3.2.2.6	Developmental Effects.....	187
3.2.2.7	Cancer.....	190
3.2.3	Dermal Exposure.....	193
3.2.3.1	Death.....	193
3.2.3.2	Systemic Effects.....	194
3.2.3.3	Immunological and Lymphoreticular Effects.....	195
3.2.3.4	Neurological Effects.....	195
3.2.3.5	Reproductive Effects.....	195
3.2.3.6	Developmental Effects.....	195
3.2.3.7	Cancer.....	195
3.3	GENOTOXICITY.....	195
3.4	TOXICOKINETICS.....	202
3.4.1	Absorption.....	203
3.4.1.1	Inhalation Exposure.....	203
3.4.1.2	Oral Exposure.....	204
3.4.1.3	Dermal Exposure.....	206
3.4.2	Distribution.....	207
3.4.3	Metabolism.....	210
3.4.4	Elimination and Excretion.....	215
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models.....	216
3.5	MECHANISMS OF ACTION.....	222
3.5.1	Pharmacokinetic Mechanisms.....	222
3.5.2	Mechanisms of Toxicity.....	223
3.5.3	Animal-to-Human Extrapolations.....	225
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS.....	226
3.7	CHILDREN'S SUSCEPTIBILITY.....	228
3.8	BIOMARKERS OF EXPOSURE AND EFFECT.....	231
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Dichlorobenzenes.....	232
3.8.2	Biomarkers Used to Characterize Effects Caused by Dichlorobenzenes.....	233
3.9	INTERACTIONS WITH OTHER CHEMICALS.....	234
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	235
3.11	METHODS FOR REDUCING TOXIC EFFECTS.....	236
3.11.1	Reducing Peak Absorption Following Exposure.....	237
3.11.2	Reducing Body Burden.....	237
3.11.3	Interfering with the Mechanism of Action for Toxic Effects.....	238
3.12	ADEQUACY OF THE DATABASE.....	239
3.12.1	Existing Information on Health Effects of Dichlorobenzenes.....	239
3.12.2	Identification of Data Needs.....	243
3.12.3	Ongoing Studies.....	254
4.	CHEMICAL AND PHYSICAL INFORMATION.....	255
4.1	CHEMICAL IDENTITY.....	255
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	255
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	263
5.1	PRODUCTION.....	263
5.2	IMPORT/EXPORT.....	265
5.3	USE.....	269

5.4	DISPOSAL	270
6.	POTENTIAL FOR HUMAN EXPOSURE	271
6.1	OVERVIEW	271
6.2	RELEASES TO THE ENVIRONMENT	275
6.2.1	Air	278
6.2.2	Water	281
6.2.3	Soil	283
6.3	ENVIRONMENTAL FATE	284
6.3.1	Transport and Partitioning	284
6.3.2	Transformation and Degradation	289
6.3.2.1	Air	289
6.3.2.2	Water	289
6.3.2.3	Sediment and Soil	291
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	294
6.4.1	Air	294
6.4.2	Water	302
6.4.3	Sediment and Soil	307
6.4.4	Other Environmental Media	310
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	311
6.6	EXPOSURES OF CHILDREN	316
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	321
6.8	ADEQUACY OF THE DATABASE	322
6.8.1	Identification of Data Needs	322
6.8.2	Ongoing Studies	325
7.	ANALYTICAL METHODS	327
7.1	BIOLOGICAL MATERIALS	327
7.2	ENVIRONMENTAL SAMPLES	331
7.3	ADEQUACY OF THE DATABASE	335
7.3.1	Identification of Data Needs	336
7.3.2	Ongoing Studies	337
8.	REGULATIONS AND ADVISORIES	338
9.	REFERENCES	346
10.	GLOSSARY	397
APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D.	INDEX	D-1

This page is intentionally blank.

LIST OF FIGURES

3-1. Levels of Significant Exposure to 1,2-Dichlorobenzene—Inhalation	61
3-2. Levels of Significant Exposure to 1,4-Dichlorobenzene—Inhalation	73
3-3. Levels of Significant Exposure to 1,2-Dichlorobenzene—Oral	114
3-4. Levels of Significant Exposure to 1,3-Dichlorobenzene—Oral	123
3-5. Levels of Significant Exposure to 1,4-Dichlorobenzene—Oral	145
3-6. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	218
3-7. Existing Information on Health Effects of 1,2-Dichlorobenzene	240
3-8. Existing Information on Health Effects of 1,3-Dichlorobenzene	241
3-9. Existing Information on Health Effects of 1,4-Dichlorobenzene	242
6-1. Frequency of NPL Sites with 1,2-Dichlorobenzene Contamination	272
6-2. Frequency of NPL Sites with 1,3-Dichlorobenzene Contamination	273
6-3. Frequency of NPL Sites with 1,4-Dichlorobenzene Contamination	274
6-4. The Decomposition of 1,4-Dichlorobenzene in Air	290
6-5. The Decomposition of 1,4-Dichlorobenzene in Soil and Water.....	292

This page is intentionally blank.

LIST OF TABLES

3-1. Levels of Significant Exposure to 1,2-Dichlorobenzene—Inhalation	55
3-2. Levels of Significant Exposure to 1,4-Dichlorobenzene—Inhalation	63
3-3. Levels of Significant Exposure to 1,2-Dichlorobenzene—Oral	103
3-4. Levels of Significant Exposure to 1,3-Dichlorobenzene—Oral	119
3-5. Levels of Significant Exposure to 1,4-Dichlorobenzene—Oral	125
3-6. Genotoxicity of Dichlorobenzenes <i>In Vivo</i>	196
3-7. Genotoxicity of Dichlorobenzenes <i>In Vitro</i>	197
3-8. Tissue Concentrations (nmol/g tissue) of Radioactivity in Male Wistar Rats at Four Time Points after Oral Administration of 10 mg/kg ¹⁴ C-Labeled 1,2-Dichlorobenzene in Corn Oil	208
3-9. Parameters in PBPK Models for 1,2-Dichlorobenzene	220
4-1. Chemical Identity of 1,2-, 1,3-, and 1,4-Dichlorobenzene	256
4-2. Physical and Chemical Properties of 1,2-, 1,3-, and 1,4-Dichlorobenzene	259
5-1. Influence of Catalysts on the Ratio 1,4-:1,2-Dichlorobenzene	264
5-2. Facilities that Produce, Process, or Use 1,2-Dichlorobenzene	266
5-3. Facilities that Produce, Process, or Use 1,3-Dichlorobenzene	267
5-4. Facilities that Produce, Process, or Use 1,4-Dichlorobenzene	268
6-1. Releases to the Environment from Facilities that Produce, Process, or Use 1,2-Dichlorobenzene	276
6-2. Releases to the Environment from Facilities that Produce, Process, or Use 1,3-Dichlorobenzene	277
6-3. Releases to the Environment from Facilities that Produce, Process, or Use 1,4-Dichlorobenzene	279
6-4. Comparison of Bioconcentration Factors (BCFs) for Various Chlorinated Benzenes in Fish	287
6-5. Levels of 1,4-Dichlorobenzene in Indoor Air	295
6-6. Levels of 1,4-Dichlorobenzene in Outdoor Air	300

6-7. Levels of 1,4-Dichlorobenzene Detected in Workplace Air.....	301
6-8. Levels of 1,2-Dichlorobenzene in Outdoor Air.....	303
6-9. Levels of 1,3-Dichlorobenzene in Outdoor Air.....	304
6-10. Concentrations of 1,4-Dichlorobenzene in Blood Samples.....	314
6-11. Dichlorobenzene Concentrations ($\mu\text{g}/\text{kg}$) in Human Placentas from Five Slovak Regions.....	317
7-1. Analytical Methods for Determining Dichlorobenzenes in Biological Materials.....	328
7-2. Analytical Methods for Determining Dichlorobenzenes in Environmental Samples.....	332
8-1. Regulations and Guidelines Applicable to Dichlorobenzenes.....	342